REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 161 filers reported holding REATA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.58 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $551,118 | -26.7% | 5,406 | -34.6% | 0.00% | 0.0% |
| Q1 2023 | $751,637 | +1197.0% | 8,269 | +432.8% | 0.00% | – |
| Q4 2022 | $57,950 | – | 1,552 | +5442.9% | 0.00% | – |
| Q3 2022 | $0 | – | 28 | -28.2% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 39 | -84.0% | 0.00% | – |
| Q1 2022 | $7,000 | +16.7% | 243 | +8.0% | 0.00% | – |
| Q4 2021 | $6,000 | -95.7% | 225 | -83.2% | 0.00% | – |
| Q3 2021 | $138,000 | -42.5% | 1,340 | -20.5% | 0.00% | -100.0% |
| Q2 2021 | $240,000 | +7.6% | 1,686 | -24.7% | 0.00% | 0.0% |
| Q1 2021 | $223,000 | -27.1% | 2,239 | -9.6% | 0.00% | 0.0% |
| Q4 2020 | $306,000 | +66.3% | 2,476 | +31.1% | 0.00% | 0.0% |
| Q3 2020 | $184,000 | +607.7% | 1,888 | +1058.3% | 0.00% | – |
| Q2 2020 | $26,000 | – | 163 | +3160.0% | 0.00% | – |
| Q1 2020 | $0 | – | 5 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |